NICE says no to BMS for second-line Orencia | InPharm
Links shared publicly online about this topic.
- 47total visits
NICE says no to BMS for second-line Orencia | InPharm
In final draft guidance NICE has not recommended the use of Bristol-Myers Squibb’s arthritis drug Orencia after other drugs have failed
View full resource at inpharm.com
Tags: Arthritis, Arthritis Medication, Rheumatoid Arthritis Medication, Drug, Orencia, Bristol-Myers Squibb
Most Recently Shared on August 25, 2011 at 11:35 am By:
NICE says no to BMS for second-line Orencia http://ow.ly/6cnhz #nice #arthritis
Advertisement
